Robert Chess - 12 May 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Reporting relationship: Director
Issuer ticker: NKTR
Reported as of: 12 May 2021
Net transaction value: -$44,320
SEC form: 4
Accepted by SEC: 14 May 2021, 18:05:25 UTC
Next SEC filing: 25 Jun 2021
Source filing: View source filing
Reporting owner signature: Mark A. Wilson, Attorney-in-Fact

Key filing fact

Robert Chess filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 14 May 2021.

Key facts

This page summarizes Robert Chess's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 May 2021, 18:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$44,320.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NKTR transaction

Common Stock

Options Exercise

Transaction value: $110,400
Shares: +8,000
Change %: +2.9%
Price: $13.80
Shares after: 288,573
Date: 12 May 2021
Ownership: Direct
Footnotes: F1

NKTR transaction

Common Stock

Sale

Transaction value: $154,720
Shares: -8,000
Change %: -2.8%
Price: $19.34
Shares after: 280,573
Date: 12 May 2021
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NKTR transaction Derivative

Stock Option

Options Exercise

Transaction value: $0
Shares: -8,000
Change %: -25%
Price: $0.000000
Shares after: 24,000
Date: 12 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $13.80
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $19.16 to $19.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.